Insurance Marketplace Realities 2025 Spring Update – Life Sciences

As AI and machine learning technologies are integrated into medical devices, there are growing concerns about the potential for malfunctions, errors or inaccurate diagnoses leading to patient harm. The liability risks associated with AI in medical devices are particularly concerning because these technologies often “learn” and evolve over time, potentially leading to unpredictable outcomes. Companies must ensure that AI-driven devices are properly tested, monitored and adjusted to minimize the risk of errors. The FDA has recently released guidance surrounding the incorporation of AI technologies throughout the medical product lifecycle in an effort to ensure product safety and effectiveness.

The rise of telemedicine and digital health platforms has also brought new product liability risks. For example, remote monitoring devices, health apps and virtual consultations can have technical issues or lead to inaccurate diagnoses, which could result in injury to patients. Companies that produce digital health tools or telemedicine platforms must navigate a complex legal landscape concerning the liability of their services and devices.

The rise of gene-editing technologies, such as CRISPR-Cas9, could revolutionize medicine. However, these technologies also raise significant product liability concerns. Companies that develop gene therapies or gene-editing tools face the challenge of ensuring their products are safe, and they must be prepared for the possibility of unforeseen consequences, such as unintended genetic changes or long-term effects on patients. The lack of long-term data on these products only increases liability risks.

As cell and gene therapies continue to evolve and receive regulatory approval, life sciences companies face heightened liability concerns. These therapies often involve complex and personalized treatments, and any adverse effects or failures could have severe consequences.

Securing product liability insurance for GLP-1 (glucagon-like peptide-1) risks presents several unique challenges due to the nature of these drugs, their widespread use and the evolving regulatory landscape.

GLP-1 medications, like semaglutide and tirzepatide, are relatively new compared to traditional medications. Despite promising clinical trials, there may still be uncertainty about their long-term safety and potential side effects. While GLP-1s have shown positive effects in managing diabetes and obesity, they have also been associated with some significant side effects, such as gastrointestinal issues. Insurance carriers may be hesitant to offer coverage or may charge higher premiums without robust, long-term data on their safety profile.

Compounding pharmacies providing GLP-1 medications face even greater underwriting scrutiny, primarily due to regulatory, safety and other business-related factors. Compounding pharmacies aren’t allowed to alter or replicate approved, commercially available drugs unless there’s a documented need such as a drug shortage. Compounding GLP-1s without the proper justification may not only lead to legal issues but also expose patients to drugs that haven’t gone through the rigorous FDA approval process for purity, dosage accuracy, or efficacy.

These challenges highlight the complexity of product liability insurance for GLP-1 manufacturers, with insurers needing to balance the innovative potential with the inherent risks and uncertainties that come with introducing new pharmaceutical products to the market.